Potential Antiviral Lignans from the Roots of Saururus chinensis with Activity against Epstein-Barr Virus Lytic Replication

被引:58
|
作者
Cui, Hui [1 ]
Xu, Bo [2 ]
Wu, Taizong [1 ]
Xu, Jun [1 ]
Yuan, Yan [2 ,3 ]
Gu, Qiong [1 ]
机构
[1] Sun Yat Sen Univ, Sch Pharmaceut Sci, Res Ctr Drug Discovery, Guangzhou 510006, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Zhongshan Sch Med, Inst Human Virol, Guangzhou 510080, Guangdong, Peoples R China
[3] Univ Penn, Sch Dent Med, Dept Microbiol, Philadelphia, PA 19104 USA
来源
JOURNAL OF NATURAL PRODUCTS | 2014年 / 77卷 / 01期
基金
中国国家自然科学基金;
关键词
NASOPHARYNGEAL CARCINOMA; TETRAHYDROFURAN LIGNANS; ABSOLUTE-CONFIGURATION; INHIBITORY-ACTIVITY; PIPER-SOLMSIANUM; ACTIVATION; NEOLIGNANS; SESQUILIGNANS; CONSTITUENTS; MANASSANTIN;
D O I
10.1021/np400757k
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Epstein-Barr virus (EBV) is a member of the gamma-herpes virus subfamily and has been implicated in the pathogenesis of several human malignancies. Bioassay-guided fractionation was conducted on an EtOAc-soluble extract of the roots of Saururus chinensis and monitored using an EBV lytic replication assay. This led to the isolation of 19 new (1-19) and nine known (20-28) lignans. The absolute configurations of the new lignans were established by Mosher's ester, ECD, and computational methods. Eight lignans, including three sesquineolignans (19, 23, and 24) and five dineolignans (3, 4, 26, 27, and 28), exhibited inhibitory effects toward EBV lytic replication with EC50 values from 1.09 to 7.55 mu M and SI values from 3.3 to 116.4. In particular, manassantin B (27) exhibited the most promising inhibition, with an EC50 of 1.72 mu M, low cytotoxicity, CC50 > 200 mu M, and SI > 116.4. This is the first study demonstrating that lignans possess anti-EBV lytic replication activity.
引用
收藏
页码:100 / 110
页数:11
相关论文
共 36 条
  • [31] Cellular Differentiation Regulator BLIMP1 Induces Epstein-Barr Virus Lytic Reactivation in Epithelial and B Cells by Activating Transcription from both the R and Z Promoters
    Reusch, Jessica A.
    Nawandar, Dhananjay M.
    Wright, Kenneth L.
    Kenney, Shannon C.
    Mertz, Janet E.
    JOURNAL OF VIROLOGY, 2015, 89 (03) : 1731 - 1743
  • [32] BSRF1 modulates IFN-β-mediated antiviral responses by inhibiting NF-κB activity via an IKK-dependent mechanism in Epstein-Barr virus infection
    Chen, Shengwen
    Deng, Yangxi
    Huang, Chen
    Xie, Xiaolei
    Long, Zhiwei
    Lao, Shuxian
    Gao, Xinghong
    Wang, Kezhen
    Wang, Shuai
    Li, Xiaoqing
    Liu, Yintao
    Xu, Chunyan
    Chen, Xinru
    Huang, Wenzhuo
    Zhang, Jian
    Peng, Tao
    Li, Linhai
    Chen, Yonger
    Lv, Xi
    Cai, Mingsheng
    Li, Meili
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2025, 306
  • [33] B cells infected with Type 2 Epstein-Barr virus (EBV) have increased NFATc1/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infection
    Romero-Masters, James C.
    Huebner, Shane M.
    Ohashi, Makoto
    Bristol, Jillian A.
    Benner, Bayleigh E.
    Barlow, Elizabeth A.
    Turk, Gail L.
    Nelson, Scott E.
    Baiu, Dana C.
    Van Sciver, Nicholas
    Ranheim, Erik A.
    Gumperz, Jenny
    Sherer, Nathan M.
    Farrell, Paul J.
    Johannsen, Eric C.
    Kenney, Shannon C.
    PLOS PATHOGENS, 2020, 16 (02)
  • [34] Antiviral activity of iridoid glycosides extracted from Fructus Gardeniae against influenza A virus by PACT-dependent suppression of viral RNA replication
    Guo, Shanshan
    Bao, Lei
    Li, Chun
    Sun, Jing
    Zhao, Ronghua
    Cui, Xiaolan
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [35] Increased association between Epstein-Barr virus EBNA2 from type 2 strains and the transcriptional repressor BS69 restricts EBNA2 activity
    Ponnusamy, Rajesh
    Khatri, Ritika
    Correia, Paulo B.
    Wood, C. David
    Mancini, Erika J.
    Farrell, Paul J.
    West, Michelle J.
    PLOS PATHOGENS, 2019, 15 (07)
  • [36] Plasma Macrophage Migration Inhibitory Factor and CCL3 as Potential Biomarkers for Distinguishing Patients with Nasopharyngeal Carcinoma from High-Risk Individuals Who Have Positive Epstein-Barr Virus Capsid Antigen-Specific IgA
    Xue, Ning
    Lin, Jian-Hua
    Xing, Shan
    Liu, Dan
    Li, Shi-Bing
    Lai, Yan-Zhen
    Wang, Xue-Ping
    Mao, Min-Jie
    Zhong, Dian
    Zeng, Mu-Sheng
    Liu, Wan-Li
    CANCER RESEARCH AND TREATMENT, 2019, 51 (01): : 378 - 390